Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases

被引:74
|
作者
Keeling, Kim M. [1 ]
Bedwell, David M. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA
关键词
MESSENGER-RNA DECAY; TRANSLATIONAL TERMINATION EFFICIENCY; PREMATURE STOP MUTATIONS; CYSTIC-FIBROSIS PATIENTS; ALPHA-L-IDURONIDASE; DYSTROPHIN EXPRESSION; CRYSTAL-STRUCTURE; READ-THROUGH; IN-VITRO; AMINOGLYCOSIDE;
D O I
10.1002/wrna.95
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Suppression therapy is a treatment strategy for genetic diseases caused by nonsense mutations. This therapeutic approach utilizes pharmacological agents that suppress translation termination at in-frame premature termination codons (PTCs) to restore translation of a full-length, functional polypeptide. The efficiency of various classes of compounds to suppress PTCs in mammalian cells is discussed along with the current limitations of this therapy. We also elaborate on approaches to improve the efficiency of suppression that include methods to enhance the effectiveness of current suppression drugs and the design or discovery of new, more effective suppression agents. Finally, we discuss the role of nonsense-mediated mRNA decay (NMD) in limiting the effectiveness of suppression therapy, and describe tactics that may allow the efficiency of NMD to be modulated in order to enhance suppression therapy. (c) 2011 John Wiley & Sons, Ltd. WIREs RNA 2011 2 837-852 DOI: 10.1002/wrna.95
引用
收藏
页码:837 / 852
页数:16
相关论文
共 50 条
  • [1] Pharmacological suppression of nonsense mutations to treat genetic diseases
    Bedwell, David Michael
    Du, Ming
    Buckley, Jessica
    Wang, Dan
    Keeling, Kim Marie
    Welch, Ellen
    Peltz, Stuart W.
    FASEB JOURNAL, 2010, 24
  • [2] Nonsense suppression therapies in ocular genetic diseases
    Xia Wang
    Cheryl Y. Gregory-Evans
    Cellular and Molecular Life Sciences, 2015, 72 : 1931 - 1938
  • [3] Nonsense suppression therapies in human genetic diseases
    Martins-Dias, Patricia
    Romao, Luisa
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2021, 78 (10) : 4677 - 4701
  • [4] Nonsense suppression therapies in ocular genetic diseases
    Wang, Xia
    Gregory-Evans, Cheryl Y.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (10) : 1931 - 1938
  • [5] Nonsense suppression therapies in human genetic diseases
    Patrícia Martins-Dias
    Luísa Romão
    Cellular and Molecular Life Sciences, 2021, 78 : 4677 - 4701
  • [6] Therapeutic molecules for the development of a read-through approach for diseases caused by nonsense mutations
    Borgatti, M.
    Breveglieri, G.
    Salvatori, F.
    Zuccato, C.
    Altamura, N.
    MINERVA BIOTECNOLOGICA, 2011, 23 (01) : 11 - 16
  • [7] Readthrough Strategies for Therapeutic Suppression of Nonsense Mutations in Inherited Metabolic Disease
    Perez, B.
    Rodriguez-Pombo, P.
    Ugarte, M.
    Desviat, L. R.
    MOLECULAR SYNDROMOLOGY, 2012, 3 (05) : 230 - 236
  • [8] Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases Progress in Development
    Rowe, Steven M.
    Clancy, John P.
    BIODRUGS, 2009, 23 (03) : 165 - 174
  • [9] Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders
    Islam, Md. Asiful
    Alam, Fahmida
    Kamal, Mohammad Amjad
    Gan, Siew Hua
    Wong, Kah Keng
    Sasongko, Teguh Haryo
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (11) : 1598 - 1609
  • [10] Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations
    Sabbavarapu, Narayana Murthy
    Shavit, Michal
    Degani, Yarden
    Smolkin, Boris
    Belakhov, Valery
    Baasov, Timor
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (04): : 418 - 423